London, March 02, 2020 (GLOBE NEWSWIRE) -- According to a new market research report “Point of Care Molecular Diagnostics Market by Product & Solution (Assay, Analyzer, Software, Services), Technology (RT-qPCR, INAAT), Application (Respiratory Diseases, Hospital Acquired Infections, STD), and End User – Global Forecast to 2027”, published by Meticulous Research®, the point of care (POC) molecular diagnostics market is expected to grow at a CAGR of 13% from 2019 to reach $2.32 billion by 2027.
Most of the diagnostic tests are carried out in central laboratories equipped with sophisticated bench-top instruments for various diseases like respiratory, sexually transmitted, cancer, hospital-acquired infections, and others. However, for getting results, patients have to stay for longer time in some instances. This leads to a delay in diagnosis and further treatment; thereby increases the mortality rate. To overcome these drawbacks, decentralized or point of care testing has been emerged.
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5081
Transition of molecular diagnostics from centralized labs to decentralized settings put major challenges in front of vendors, as molecular diagnosis is highly related to genes, molecular markers, and DNA/RNA expressions. Using various technologies like RT-qPCR, isothermal amplification technology among others, vendors developed molecular diagnostics tests at point of care settings. This helps physicians to further improve the standard of care by combining the ability to quickly make a diagnosis and treatment decision during the patient’s initial visit rather than having to wait for hours.
The POC molecular diagnostics market study presents historical market data in terms of value (2017, and 2018), estimated current data (2019), and forecasts for 2027 - by product & solution, technology, application, and end-user. The study also evaluates industry competitors and analyzes the market at the regional and country level.
On the basis of technology, the RT-qPCR segment held the largest share of the POC molecular diagnostics market in 2019. The largest share of this segment is mainly attributed to its features of identifying amplified fragments in real-time and in more specific, sensitive, and reproducible way compared to traditional PCR. Moreover, large number of commercially available RT-qPCR based POC molecular diagnostic systems or tests, growing need for rapid diagnosis of viral & infectious diseases, and increasing utilization of RT-qPCR in proteomics & genomics are some of the other factors expected to drive the growth of this technology.
On the basis of product and solution, kits & assays expected to grow at the highest CAGR during the forecast period owing to their frequent and repetitive usage, growing focus on commercializing disease-specific assays for early diagnosis, technological advancements, and focus on receiving CLIA approvals for disease-specific POC molecular diagnostic products.
On the basis of application, respiratory diseases commanded the largest share of the overall POC molecular diagnostics market in 2019, attributed to the fact that number of respiratory infectious diseases associated with aging population and environmental factors is growing continuously. This leads to the increase in the number of commercialized infectious disease specific POC molecular diagnostic products in the market.
Based on the end user, clinics and diagnostic laboratories commanded the largest share of the overall POC molecular diagnostics market in 2019, followed by hospital outpatient departments and intensive care units (ICUs), research and academic institutes, and other end users. The factors such as increasing focus of key companies on offering disease specific POC molecular diagnostics to cater larger customer base, growing demand for POC technologies to be used within the physician’s offices or associated diagnostic labs, and growing awareness regarding early diagnosis contributed to the largest share of the clinics and diagnostic laboratories in this market.
Geographically, North America dominated the overall POC molecular diagnostics market in 2019, followed by Europe and Asia Pacific. The factors such as growing awareness about the early diagnosis of chronic diseases, rising number of cases with infectious diseases, increasing venture capital funding, development and commercialization of CLIA-waived tests/systems, and strong presence of key players in this region supported the largest share of North America in the POC molecular diagnostics market. However, POC molecular diagnostics market in Asia Pacific region is expected to grow at the fastest CAGR during the forecast period. The key factors driving the growth of this market are rising incidences of chronic diseases associated with geriatric population, expansion of key market players in this region, insufficient sophisticated central laboratory testing services, and potential cost effectiveness of POC molecular diagnosis.
The report also includes extensive assessment of the product portfolio, geographic analysis, and key strategic developments adopted by the leading market participants in the industry over the past 4 years (2016–2019). The POC molecular diagnostics market has witnessed number of new product launches; approvals; agreements, partnerships, and collaborations; and expansions and acquisitions in the recent years. For instance, in October 2019, Cepheid (U.S.) received clearance from the U.S. Food and Drug Administration for Xpert BCR-ABL Ultra. This helped monitoring of BCR-ABL levels in patients with Chronic Myeloid Leukemia (CML) under 3 hours. In July 2017, F. Hoffmann-La Roche Ltd (Switzerland) launched cobas MRSA/SA nucleic acid assay for the qualitative detection and differentiation of methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus aureus (SA) at the point of care on cobas Liat PCR System.
The key players operating in the global POC molecular diagnostics market are Alere Inc. (U.S.), DxNA, LLC. (U.S.), Mesa Biotech Inc. (U.S.), Meridian Bioscience Inc. (U.S.), Danaher Corporation (U.S.), Quidel Corporation (U.S.), Biocartis Group NV (Belgium), bioMérieux SA (France), Thermo Fisher Scientific (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland), among others.
To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/point-of-care-molecular-diagnostics-market-5081/
Scope of the Report:
POC Molecular Diagnostics Market by Technology
- Real-Time Polymerase Chain Reaction (RT-qPCR),
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Other Technologies
POC Molecular Diagnostics Market by Product & Solution
- Kits & Assays
- Analyzers
- Software & Services
POC Molecular Diagnostics Market by Application
- Respiratory Diseases
- Sexually Transmitted Diseases
- Cancer/Oncology
- Hospital Acquired Infections
- Neonatal/Prenatal Testing
- Other Applications
POC Molecular Diagnostics Market by End User
- Clinics and Diagnostic Laboratories
- Hospital Outpatient Departments and Intensive Care Units (ICUs)
- Research and Academic Institutes
- Other End Users
POC Molecular Diagnostics Market by Geography
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe (RoE)
- Asia-Pacific (APAC)
- Japan
- China
- India
- Rest of APAC (RoAPAC)
- Latin America
- Middle East & Africa
Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5081
Key questions answered in the report-
- Which are the high growth market segments in terms of product & solution, technology, application, end-users, and region/countries?
- What was the historical market for point of care molecular diagnostics across the globe?
- What are the market forecasts and estimates for the period 2019-2027?
- What are the major drivers, restraints, opportunities, and challenges in the global point of care molecular diagnostics market?
- Who are the major players in the point of care molecular diagnostics market?
- How is the competitive landscape and who are the market leaders in the global point of care molecular diagnostics market?
- What are the recent developments in the global point of care molecular diagnostics market?
- What are the different strategies adopted by the major players in the global point of care molecular diagnostics market?
- What are the geographic trends and high growth regions/ countries?
Related Reports:
Microfluidic Immunoassay Market by Product Type (Lab-on-chip, POC Analyzers, Reagents, and Assay), Technology, Application (Cardiac, Troponin, BNP) – Global Forecast to 2025
Immunoassay Market by Product (Kits and Reagents, Analyzers, Software), Platform (Chemiluminescence, Radioimmunoassays) Application (Infectious Diseases, Cardiology), End-User (Hospitals, Academic Laboratories), and Geography - Global Forecast to 2025
Point of Care Diagnostics Market by Test (Glucose, Cardiac, HbA1c, HIV, STD, HCV, Pregnancy, Cancer, Hematology), Platform (Immunoassay, Microfluidics, MDx), Mode (Prescription, OTC), End-User (Hospital, At Home, OPD) – Global Forecast To 2024
Tissue Diagnostics Market by Product (Consumables, Instruments), Technology (Immunohistochemistry, in Situ Hybridization, Digital Pathology and Workflow), Disease (Breast Cancer, Gastric Cancer, Lymphoma), End-User (Hospital, CRO) - Global Forecast to 2024
Allergy Diagnostics Market by Product (Assay Kits, Immunoassay and Elisa Analyzers, Luminometers, Services), Allergens (Food, Inhaled, Drug), Tests (In Vivo, In Vitro), End Users (Hospital, Diagnostic Laboratory, Research) - Global Forecast to 2024
Label-Free Detection Market by Product (Consumables and Instruments), by Technology, (Surface Plasmon Resonance, Bio-Layer Interferometry, Cellular Dielectric Spectroscopy, Electrical Impedance Spectroscopy, Optical Waveguide Grating Technology, and others), by Application, (Binding Kinetics, Hit Confirmation, Lead Generation, Endogenous Receptor Detection, Binding Thermodynamics, and others), and by End user - Global Forecast to 2022
About Meticulous Research®
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze and present the critical market data with great attention to details.
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, with the help of its unique research methodologies, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa regions.
With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.